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H
umans have the greatest fat content of any
mammalian species at birth (1). It has been
known for many years that abnormally high
maternal glucose (as is the case when the
mother has type 1 or type 2 diabetes during pregnancy) is
characteristically associated with increased fat deposition
in utero. In pioneering work in the 1950s, Pedersen (2)
suggested that in the offspring of mothers with diabetes,
excess fetal insulin production was key in promoting fetal
overgrowth. Speciﬁcally, maternal hyperglycemia led to
excess exposure of the fetus to maternal glucose, fetal
hyperinsulinemia, and excess growth. The Pedersen hy-
pothesis was later modiﬁed by Freinkel and Metzger, who
added a potential role of other nutrients to fetal over-
growth in diabetic pregnancy (3); however, the central role
of fetal hyperinsulinism and control of maternal glucose
remained. The potential clinical importance of maternal
glycemia and fetal overgrowth has increased, since it
became apparent that exposure to maternal diabetes could
exert long-term effects on the offspring, increasing the risk
of type 2 diabetes and obesity (4,5).
Gestational diabetes—diabetes with ﬁrst onset or rec-
ognition during pregnancy (6)—has long been a contro-
versial clinical area. Methods of screening for gestational
diabetes, the speciﬁc tests used, and even the biochemical
deﬁnition of diabetes during pregnancy have varied be-
tween and indeed within countries. Such controversies
usually ﬂourish in the absence of high-quality evidence,
and in this case, the uncertainties have reﬂected a lack of
large, suitably designed, observational, and randomized
control trials. There have been particular problems with
the interpretation of previous observational trials as the
diagnosis of gestational diabetes itself likely alters medical
and particularly obstetric practice, rendering outcomes
such as rates of caesarean section difﬁcult to assess (7).
Happily, the evidence base has improved hugely in recent
years. In 2005, Crowther et al. (8) provided clear evidence
that diagnosis of glucose abnormality in pregnancy and
management designed to lower blood glucose resulted in
modiﬁcation of birth weight and indeed improvement in
perinatal outcomes. More recently, the Hyperglycemia and
Adverse Pregnancy Outcomes (HAPO) investigators have
completed an extensive data collection examining the
relationship of maternal glucose, measured by a 75-g oral
glucose tolerance test, to neonatal outcomes. The HAPO
investigators have already demonstrated a continuous
graded relationship between maternal glucose and the
primary outcomes of the study, including fetal insulin (as
assessed by cord C-peptide at birth) and macrosomia (9).
In this issue of Diabetes, the HAPO investigators examine
the relationship of maternal glucose and fetal insulinemia
(as deﬁned by umbilical cord C-peptide) to fetal adiposity
(10). The investigators show a continuous relationship
between maternal glycemia and neonatal adiposity, similar
to that described for macrosomia. Further, there is a
continuous relationship between neonatal insulin and ad-
iposity either by skinfolds or derived percent body fat at
birth.
The investigators are once again to be congratulated on
this landmark study. Key strengths of the HAPO study
include its large size and the diverse populations studied
using a single research protocol. A critical (and difﬁcult to
achieve) design feature is that glucose results of the
majority of women in the HAPO study remained blinded,
reducing the risk of bias arising from changes in clinical
behaviors secondary to the perceived risks relating to
maternal glycemia (9). Several points emerge. First, it is
encouraging, and perhaps even surprising, that maternal
glucose measured at a single point in pregnancy is so
effective at predicting birth outcomes, as was also the case
in the investigators’ ﬁrst publication (9). Second, the
current study conﬁrms the relationship of maternal glu-
cose, neonatal insulin, and adiposity and the important
role of fetal insulin in growth, suggested by Pedersen.
Notably, however, these relationships appear to be present
in a graded fashion across the spectrum of maternal
glycemia. Thus, maternal glucose appears to be inﬂuenc-
ing fetal growth, insulin, and adiposity not just when
mother’s glucose is “high,” but in a continuous manner
across all levels of glucose. For example, the likelihood of
neonatal skinfolds above the 90th percentile increased by
almost 40% when maternal fasting glucose at the oral
glucose tolerance test was 4.2–4.4 mmol/l compared with
4.2 mmol/l. Maternal glucose emerges as a key determi-
nant of growth and adiposity. From a scientiﬁc perspec-
tive, this suggests that the mechanisms proposed by
Pedersen are important in the control of fetal growth and
adiposity, not just in overt maternal diabetes but across
the normal population, and are potentially a central part of
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302 DIABETES, VOL. 58, FEBRUARY 2009the way that fetal growth is regulated. One of the interest-
ing implications of this relates to fetal programming. High
levels of maternal glucose increase the risk of excess
adiposity and abnormal glucose tolerance in maternal type
1 diabetes (11) and type 2 diabetes (4,5) and inﬂuence the
penetrance of genetic syndromes of diabetes (12). Risks of
excess adiposity have in turn been related to fetal hyper-
insulinemia (13). Given the HAPO results, it is reasonable
to wonder how far into the range of maternal glucose such
programming effects might occur and more provocatively
whether clinical management affects them. Similarly, our
high fat content at birth and the difference in fat between
ourselves and our closest evolutionary relatives suggest
that relatively high neonatal fat content has been advan-
tageous to us in our recent evolutionary history (1). It is
suggested that part of this advantage may be explained by
the increased metabolic demands inherent in the relatively
large human brain at birth (1). What then is optimal fatness
at birth for short- and long-term outcomes? Follow-up of
children in the HAPO cohort will be critical.
Finally, it is hoped and expected that the detailed analysis
of the HAPO study will support international agreement on a
single deﬁnition of gestational diabetes. Future publications
of the HAPO group should allow deﬁnition of the relative
roles of fasting, 1- and 2-h glucose in prediction of adverse
outcomes, and interaction with these and other risk factors.
The process of achieving consensus will be challenged by the
continuous relationships with outcomes. Nevertheless, the
considerable strengths of the HAPO study should allow
the investigators and the clinical community the best avail-
able opportunity to deﬁne the level of glycemia at which
diagnosis and intervention may improve outcomes for
mother and child.
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